|
|
|
|
| LEADER |
05520nma a2201837 u 4500 |
| 001 |
EB002156881 |
| 003 |
EBX01000000000000001294996 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
230515 ||| eng |
| 020 |
|
|
|a books978-3-0365-6374-9
|
| 020 |
|
|
|a 9783036563749
|
| 020 |
|
|
|a 9783036563756
|
| 100 |
1 |
|
|a Pantazopoulos, Ioannis
|
| 245 |
0 |
0 |
|a Respiratory and Critical Care
|h Elektronische Ressource
|
| 260 |
|
|
|a Basel
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2023
|
| 300 |
|
|
|a 1 electronic resource (322 p.)
|
| 653 |
|
|
|a cardiovascular dynamics
|
| 653 |
|
|
|a medical masks
|
| 653 |
|
|
|a vaccine-induced immunity
|
| 653 |
|
|
|a rest volume
|
| 653 |
|
|
|a sputum
|
| 653 |
|
|
|a anesthesiology
|
| 653 |
|
|
|a idiopathic pulmonary fibrosis
|
| 653 |
|
|
|a recovery
|
| 653 |
|
|
|a human
|
| 653 |
|
|
|a length of stay
|
| 653 |
|
|
|a pulmonary fibrosis
|
| 653 |
|
|
|a pandemic
|
| 653 |
|
|
|a COPD
|
| 653 |
|
|
|a antituberculotic drugs
|
| 653 |
|
|
|a acute respiratory distress syndrome
|
| 653 |
|
|
|a one-lung ventilation
|
| 653 |
|
|
|a propofol
|
| 653 |
|
|
|a obstructive sleep apnea (OSA)
|
| 653 |
|
|
|a digitalization of healthcare
|
| 653 |
|
|
|a urokinase plasminogen activator receptor
|
| 653 |
|
|
|a FEV1
|
| 653 |
|
|
|a mandibular advancement devices (MADs)
|
| 653 |
|
|
|a prediction of bleeding
|
| 653 |
|
|
|a outcomes
|
| 653 |
|
|
|a lung aging
|
| 653 |
|
|
|a sarcopenia
|
| 653 |
|
|
|a mortality
|
| 653 |
|
|
|a SARS-CoV-2
|
| 653 |
|
|
|a inspiratory muscle training
|
| 653 |
|
|
|a low muscle mass
|
| 653 |
|
|
|a latent tuberculosis
|
| 653 |
|
|
|a asthma
|
| 653 |
|
|
|a severity
|
| 653 |
|
|
|a Pharmaceutical industries / bicssc
|
| 653 |
|
|
|a control
|
| 653 |
|
|
|a expiratory muscle training
|
| 653 |
|
|
|a interferon-inducible protein-10
|
| 653 |
|
|
|a intensive care medicine
|
| 653 |
|
|
|a prognosis
|
| 653 |
|
|
|a sleep deprivation
|
| 653 |
|
|
|a clinical outcomes
|
| 653 |
|
|
|a vitamin D
|
| 653 |
|
|
|a C-reactive protein (CRP)
|
| 653 |
|
|
|a anticoagulant treatment
|
| 653 |
|
|
|a tuberculosis
|
| 653 |
|
|
|a exacerbations
|
| 653 |
|
|
|a cough
|
| 653 |
|
|
|a supine position
|
| 653 |
|
|
|a eosinophil blood count
|
| 653 |
|
|
|a influenza
|
| 653 |
|
|
|a community-acquired pneumonia (CAP)
|
| 653 |
|
|
|a PM2.5
|
| 653 |
|
|
|a stressed volume
|
| 653 |
|
|
|a respiratory muscle training
|
| 653 |
|
|
|a inflammatory rheumatoid disease
|
| 653 |
|
|
|a diffuse alveolar damage
|
| 653 |
|
|
|a host immune response
|
| 653 |
|
|
|a respiratory diseases
|
| 653 |
|
|
|a breakthrough COVID-19 hospitalizations
|
| 653 |
|
|
|a mean circulatory filling pressure
|
| 653 |
|
|
|a cardiovascular infections
|
| 653 |
|
|
|a diaphragmatic thickness fraction
|
| 653 |
|
|
|a cloth masks
|
| 653 |
|
|
|a vaccination
|
| 653 |
|
|
|a risk factors
|
| 653 |
|
|
|a adults
|
| 653 |
|
|
|a effectiveness
|
| 653 |
|
|
|a antibody
|
| 653 |
|
|
|a chronic obstructive pulmonary disease
|
| 653 |
|
|
|a virus diseases
|
| 653 |
|
|
|a sevoflurane
|
| 653 |
|
|
|a immunization
|
| 653 |
|
|
|a cognitive impairment
|
| 653 |
|
|
|a inflammation
|
| 653 |
|
|
|a N95 masks
|
| 653 |
|
|
|a septic shock
|
| 653 |
|
|
|a emergency department
|
| 653 |
|
|
|a in-hospital bleeding
|
| 653 |
|
|
|a n/a
|
| 653 |
|
|
|a troponin
|
| 653 |
|
|
|a ischemia modified albumin
|
| 653 |
|
|
|a diagnosis
|
| 653 |
|
|
|a hospitalization
|
| 653 |
|
|
|a cognitive
|
| 653 |
|
|
|a dyspnea
|
| 653 |
|
|
|a air pollution
|
| 653 |
|
|
|a upper respiratory infections
|
| 653 |
|
|
|a FFP masks
|
| 653 |
|
|
|a fractional exhaled NO
|
| 653 |
|
|
|a pulmonary rehabilitation
|
| 653 |
|
|
|a transmission
|
| 653 |
|
|
|a β-Thalassemia
|
| 653 |
|
|
|a intubation
|
| 653 |
|
|
|a Factor VIII
|
| 653 |
|
|
|a microRNAs
|
| 653 |
|
|
|a cardiovascular
|
| 653 |
|
|
|a infection
|
| 653 |
|
|
|a venous thromboembolism
|
| 653 |
|
|
|a COVID-19
|
| 653 |
|
|
|a iloprost
|
| 653 |
|
|
|a pulmonary embolism
|
| 653 |
|
|
|a respiratory side effects
|
| 653 |
|
|
|a pneumonia
|
| 653 |
|
|
|a D-dimers
|
| 653 |
|
|
|a biomarkers
|
| 653 |
|
|
|a SARS-CoV-2 IgG Spike responses
|
| 653 |
|
|
|a mechanical ventilation
|
| 653 |
|
|
|a critical care
|
| 653 |
|
|
|a masks
|
| 653 |
|
|
|a dental effects
|
| 653 |
|
|
|a respiratory disease
|
| 653 |
|
|
|a venous return
|
| 653 |
|
|
|a unstressed volume
|
| 653 |
|
|
|a bleeding complications
|
| 653 |
|
|
|a exercise
|
| 653 |
|
|
|a skeletal effects
|
| 653 |
|
|
|a microparticles
|
| 653 |
|
|
|a oxygenation
|
| 653 |
|
|
|a ICU admission
|
| 653 |
|
|
|a oxidative stress
|
| 653 |
|
|
|a hemodynamics
|
| 653 |
|
|
|a histology
|
| 653 |
|
|
|a lung mechanics
|
| 653 |
|
|
|a usTnT
|
| 653 |
|
|
|a thyroidectomy
|
| 653 |
|
|
|a open lung biopsy
|
| 700 |
1 |
|
|a Kotsiou, Ourania S.
|
| 700 |
1 |
|
|a Pantazopoulos, Ioannis
|
| 700 |
1 |
|
|a Kotsiou, Ourania S.
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 028 |
5 |
0 |
|a 10.3390/books978-3-0365-6374-9
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/96661
|z DOAB: description of the publication
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/6606
|7 0
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 140
|
| 082 |
0 |
|
|a 700
|
| 520 |
|
|
|a This reprint provides important scientific information across all areas of respiratory research including COVID-19, COPD, asthma, pulmonary embolism, pneumonia, sleep medicine and respiratory critical care.
|